Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Bank of America

Key Points

• Bank of America raised Gilead Sciences’ price target to $172 from $168 while maintaining a “Buy” rating, implying 12.37% upside from the prior close.
• Analyst sentiment remains favorable overall: 23 analysts rate the stock “Buy” and six rate it “Hold,” producing a consensus “Moderate Buy” rating and $159.63 target price.
• Gilead reported quarterly revenue of $7.80 billion, ahead of expectations, although it posted a loss per share and continues to face profitability concerns. Insiders have sold 111,000 shares worth approximately $15.9 million over the past 90 days.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its target price raised by Bank of America from $168.00 to $172.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. Bank of America's price objective indicates a potential upside of 12.37% from the company's previous close.

Several other equities research analysts have also recently issued reports on GILD. Truist Financial lifted their price objective on shares of Gilead Sciences from $150.00 to $158.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $160.00 to $170.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. Zacks Research cut shares of Gilead Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 29th. Weiss Ratings upgraded shares of Gilead Sciences from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, September 14th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $159.63.

Gilead Sciences Stock Down 2.0%

Shares of GILD opened at $153.07 on Tuesday. The business's 50 day moving average is $147.59 and its 200 day moving average is $137.39. The company has a market capitalization of $189.80 billion, a PE ratio of -57.33 and a beta of 0.31. Gilead Sciences has a 12-month low of $114.02 and a 12-month high of $160.51. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same period in the previous year, the firm earned $2.01 EPS. The firm's revenue was up 10.6% compared to the same quarter last year. Research analysts expect that Gilead Sciences will post -0.47 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the chief financial officer directly owned 161,096 shares in the company, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the firm's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares of the company's stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Client 1ST Advisory Group LLC lifted its position in shares of Gilead Sciences by 4.0% during the 3rd quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company's stock valued at $266,000 after buying an additional 69 shares during the last quarter. Davidson Trust Co. grew its stake in shares of Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company's stock worth $262,000 after acquiring an additional 74 shares during the period. Grove Bank & Trust increased its holdings in Gilead Sciences by 1.2% in the 3rd quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company's stock worth $946,000 after acquiring an additional 74 shares during the last quarter. Financial Connections Group Inc. increased its holdings in Gilead Sciences by 30.2% in the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 76 shares during the last quarter. Finally, Wilkerson Advisory Group LLC raised its stake in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 78 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Ulcerative colitis trial success: Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The data strengthen Gilead’s inflammatory bowel disease pipeline and could support a broader growth opportunity beyond its core HIV franchise. Gilead's pill succeeds in mid-stage bowel disease trial
• Positive Sentiment: FDA approval momentum: Recent regulatory wins include approval of the Bixlenvo HIV regimen, a first-line label expansion for Trodelvy in metastatic triple-negative breast cancer, and approval of Hepcludex for chronic hepatitis delta. These decisions expand Gilead’s commercial opportunities across HIV, oncology and liver disease. How Investors Are Reacting To Gilead Sciences FDA Drug Approvals
• Positive Sentiment: Analyst and institutional support: Zacks upgraded Gilead to Rank #2, or “Buy,” citing improving earnings prospects. In addition, 43 exchange-traded funds added GILD shares, potentially providing incremental buying demand. Gilead rating upgrade to Buy
• Neutral Sentiment: Upcoming research disclosures: Gilead plans to present 28 studies at IDWeek 2026, covering HIV treatment, prevention and emerging antiviral programs. The event could provide additional catalysts, although the financial impact depends on the data and eventual commercialization.
• Negative Sentiment: Acquisition and profitability concerns: Investors remain focused on the cost of recent acquisitions, including Arcellx and Tubulis. Those deals have increased research expenses and contributed to a reported trailing 12-month loss, raising questions about near-term earnings and whether the acquisitions can generate sufficient returns. What Has Changed About Owning Gilead Stock?

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.